To determine the impact of reduced CCL2 activity on tumor growth when combined with anti-PD-1, we depleted CCL2 expression in NA13 cells using either of two different shRNAs (Supplementary Fig. 4a). The gene discussed is PDCD1; the disease is neoplasm.